

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Tumor treating fields promote antitumor activity via which of the following mechanisms?
 - a. Disruption of cell migration
 - b. Enhancement of antitumor immunity
 - c. Interference with mitosis
 - d. Increased membrane permeability
 - e. All of the above

2. Sodium-dependent phosphate transport protein NaPi2b, the target of the antibody-drug conjugate upifitamab rilsodotin, is expressed in approximately what fraction of high-grade serous ovarian cancer?
 - a. 10%
 - b. 25%
 - c. 40%
 - d. Greater than 60%

3. Based on Phase III data, which of the following types of adverse events of special interest is most commonly observed in patients receiving mirvetuximab soravtansine for platinum-resistant ovarian cancer?
 - a. Dermatologic
 - b. Neurologic
 - c. Ocular
 - d. Respiratory

4. The Phase II MEDIOLA trial evaluating olaparib and durvalumab with or without bevacizumab for patients with germline BRCA wild-type, platinum-sensitive relapsed ovarian cancer demonstrated which of the following outcomes?
 - a. The confirmed objective response rate (ORR) was greater with the triplet than the doublet
 - b. The confirmed ORR was about the same with the triplet and the doublet
 - c. The confirmed ORR was lower with the triplet than the doublet

5. The Phase III PRIME trial demonstrated an increase in median progression-free survival of approximately how many months for patients in the intent-to-treat population receiving maintenance niraparib compared to placebo for newly diagnosed advanced ovarian cancer?
 - a. 4.5
 - b. 8
 - c. 16.5
 - d. 24